Health ProductsPublic Communication

Thelin (sitaxsentan sodium) - Worldwide Product Withdrawal - For the Public

· Published by Health Canada · Official notice

Details

Alert type: Public Communication
Category: Drugs
Audience: General Public
Department: Health Canada
Get told about the next health product recall.

We email or text you when Canada issues a recall that matches what you watch: a brand, a product, an allergen. Most never make the news.

Get health product recall alerts

CA$3.99/mo · cancel anytime

Introduction

This is duplicated text of a letter from Pfizer Canada Inc.
Contact the company for a copy of any references, attachments or enclosures.

Notice about Health Canada advisories

Details

Public Communication - Health Canada Endorsed Important Safety Information on THELIN: Withdrawal in Canada

December 20, 2010

Subject: Pfizer Initiates Product Withdrawal of THELIN® (sitaxsentan sodium) Worldwide

Pfizer Canada, in collaboration with Health Canada, has decided to voluntarily withdraw THELIN® (sitaxsentan sodium) tablets from the Canadian market due to concerns of liver damage. THELIN® is an oral medication used in the treatment of pulmonary arterial hypertension (PAH).

  • If you are a patient currently taking THELIN® you should contact your healthcare professional immediately to discuss other therapies to treat your PAH. THELIN® will remain available to you during your transition to other therapy.
  • Do not stop taking THELIN® until you speak with your doctor.
  • Contact your doctor immediately if you have any of the following symptoms: nausea, vomiting, loss of appetite, fever, unusual tiredness, abdominal pain, or yellow coloring of the skin or eyes (known as jaundice). These may be signs that your liver is not functioning properly. Your doctor may conduct blood tests to check that your liver is working properly.

While liver damage is a known complication of THELIN® therapy, Pfizer recently became aware of new safety information that led the company to conclude that the benefit of this medicine no longer outweighs the risk for the general population of patients with PAH. Because this potentially life-threatening liver injury is unpredictable, and given the availability of other treatment options for PAH, Pfizer decided to remove THELIN® from the market.

In the interest of patient safety, Pfizer will be discontinuing availability of THELIN® in all countries where it is approved. Pfizer will also be discontinuing all clinical studies of THELIN®.

Managing marketed health product-related adverse reactions depends on health care professionals and consumers reporting them. Reporting rates determined on the basis of spontaneously reported post-marketing adverse reactions are generally presumed to underestimate the risks associated with health product treatments. Any case of serious or unexpected adverse reactions in patients receiving THELIN® should be reported to Pfizer Canada or Health Canada at the following addresses:

Pfizer Canada Inc.
17300 Trans-Canada Highway
Kirkland, QC H9J 2M5
Telephone: 1-800-463-6001

You can report any suspected adverse reactions associated with the use of health products to the Canada Vigilance Program by one of the following three ways:

  • Report online at www.healthcanada.gc.ca/medeffect
  • Call toll-free at 1-866-234-2345
  • Complete a Reporting Form and:
    • Fax toll-free to 1-866-678-6789, or
    • Mail to: Canada Vigilance Program
      Health Canada
      Postal Locator 0701E
      Ottawa, Ontario K1A 0K9

The Reporting Forms, postage paid labels, and Guidelines can be found on the MedEffect™ Canada Web site in the Adverse Reaction Reporting section.

For other health product inquiries related to this communication, please contact Health Canada at:
Marketed Health Products Directorate
E-mail: mhpd_dpsc@hc-sc.gc.ca
Telephone: 613-954-6522
Fax: 613-952-7738

For medical or pharmaceutical requests please contact Pfizer Canada Inc's Medical Information Department at 1-800-463-6001.

Sincerely,

original signed by

Bernard Prigent, MD, MBA
Vice-President and Medical Director
Pfizer Canada Inc.

Get told about the next health product recall.
Get health product recall alerts

CA$3.99/mo · cancel anytime